Save Article

According to the latest rankings, cannabis health and wellness company Aleafia Health Inc. (TSX:ALEF) scores the top spot for best performing stock on the TSX Venture Exchange in the period from December 31, 2017 to December 31, 2018

Vasudha Sharma | March 4, 2019 | SmallCapPower: Cannabis company Aleafia Health Inc. (TSX:ALEF) has been named the 2019 TSX Venture 50 top performing company of the year. According to annual performance rankings of the TSX Venture Exchange, Aleafia Health recorded the best market performance during 2018 among all other companies that fall in the Clean Technology and Life Sciences category. In 2018, Aleafia Health’s share price grew by 107%, even touching a high of $4.70 per share.

Hear directly from Investor Relations at Aleafia Health Inc. (TSX:ALEF) Sign up for our FREE daily investment newsletter We will never share your data with a third-party without your consent. Leave this field empty if you're human:

The TSX Venture Exchange evaluated companies based on growth in their market capitalization, appreciation in their share price and the amount of trading volume during 2018. The list covers five industry sectors with 10 companies in each. And with Aleafia Health at the #1 spot, this is the first time that a cannabis company has bagged such a distinction.



What drove Aleafia’s chart-topping market performance in 2018

This acknowledgement from the market comes on the back of Aleafia Health checking off its major targets during the past year. A licensed producer, Aleafia made its first ever sale of medical cannabis to CannTrust Holdings Inc. (TSX:TRST) in September 2018, days after receiving a sales licence from Health Canada. According to Aleafia, this sale led to a 36% increase in the Company’s revenue.

Also that month, Aleafia Health partnered with Cronos Group to study the effects of medical cannabis on insomnia and sleep patterns, launching Aleafia Labs to serve as its research hub. Every move Aleafia made in 2018 was towards a gaining a scientific leadership in medical cannabis. The Company is focused on developing cannabis therapies to tackle the addiction epidemic of opioids and prescription drugs.

This emphasis on affecting a cultural shift towards medical cannabis ties in well with Aleafia Health’s clinic business, run under the name Canabo Medical Clinic. Its Canada-wide network of medical cannabis clinics reached the milestone mark of 50,000 patients in 2018 with the help of expanded telemedicine solutions and a growing medical staff. The Company’s access to medical cannabis patients is one of a kind. They own the largest medical cannabis patient dataset in the world, allowing them to leverage those consumer insights to tackle troubling health trends and develop unique products and treatment methods.

Aleafia’s recent acquisition of cannabis company Emblem Corp takes its patient count to 60,000 patients. Emblem also introduces high-quality derivative products, including capsules, oils and oral sprays to Aleafia’s portfolio, which Aleafia patients can purchase in an integrated platform. Emblem’s award-winning customer service and its eCommerce platform are also a great value-add to Aleafia’s clinic practice.

A new medical cannabis leader in the making?

Its cannabis production capacity also got a major boost during the past year with the acquisition of a 160,000 sq. ft. Niagara Greenhouse facility. This January, Aleafia Health completed Phase I of construction and retrofitting of 60,000 sq. ft of this facility. It will feature an automated grow system for a year-round harvest. Aleafia’s Niagara site and its other grow facility at Port Perry enable it to grow 98,000 kg of cannabis flower in 2019. And now with Emblem’s Paris, Ontario facility in its kitty, Aleafia is fully funded to grow up to 138,000 kg this year.

Aleafia Health also has global ambitions, whose wheels it set in motion in 2018. Serruya Private Equity recently invested $10 million in Aleafia Health to help the Company launch 20 retail outlets and expand internationally. After cannabis cultivation, research and development, and medical clinics, this is Aleafia’s foray into adult-use cannabis.

For Our Complete Coverage Of Canadian Marijuana Stocks Click Here

With Aleafia Health at the forefront of medical cannabis research, it has also decided to encourage cannabis awareness using its extensive patient experience. The Company is working on offering a cloud-based learning platform to provide courses such as Cannabis 101, Cannabis in the Workplace, Patient Dosing and others. Aleafia has tied up with D2L (Desire2Learn) Corporation to execute its vision of building a global cannabis education platform.

A new growth manifesto

Aleafia Health also recently released its manifesto ‘We Grow Together’. It’s a message of strength and purpose aimed at shareholders and Canadians in general. The Company takes its role seriously in driving a transformational change in the consumer cannabis experience. They want to change lives by giving the people a better and scientific way to heal. Aleafia wants to become the world’s best health and wellness consumer cannabis experience with the help of its integrated science and data approach. Science is seeding wellness at Aleafia Health. And the shoots of growth are being appreciated by the market.

To find out more about Aleafia Health Inc. (TSX:ALEF) please visit the company’s Investor Hub.

Hear directly from Investor Relations at Aleafia Health Inc. (TSX:ALEF) Sign up for our FREE daily investment newsletter We will never share your data with a third-party without your consent. Leave this field empty if you're human:

Aleafia Health Inc. (TSX:ALEF) is a featured sponsored company and has paid SmallCapPower.com a fee for coverage. To learn more, see our full disclosure HERE >>

To read our full disclosure, please click on the button below:

DISCLOSURE

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.